<SUBMISSION>
<ACCESSION-NUMBER>0001104659-09-003180
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090120
<ITEMS>2.02
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20090121
<DATE-OF-FILING-DATE-CHANGE>20090121
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>OMNICELL, Inc
<CIK>0000926326
<ASSIGNED-SIC>3571
<IRS-NUMBER>943166458
<STATE-OF-INCORPORATION>CA
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-33043
<FILM-NUMBER>09535719
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1201 CHARLESTON ROAD
<CITY>MOUNTAIN VIEW
<STATE>CA
<ZIP>94043-1337
<PHONE>6502516100
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1201 CHARLESTON ROAD
<CITY>MOUNTAIN VIEW
<STATE>CA
<ZIP>94043-1337
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>OMNICELL INC /CA/
<DATE-CHANGED>20010625
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>OMNICELL COM /CA/
<DATE-CHANGED>20000419
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>OMNICELL TECHNOLOGIES INC
<DATE-CHANGED>19960807
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a09-3556_18k.htm
<DESCRIPTION>8-K
<TEXT>

<html>

<head>





</head>

<body lang="EN-US" style="text-justify-trim:punctuation">

<div>

<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;color:black;font-size:12.0pt;margin:0in 0in .0001pt;padding:1.0pt 0in 1.0pt 0in;text-autospace:none;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED&nbsp;STATES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES&nbsp;AND&nbsp;EXCHANGE&nbsp;COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington,
D. C.&nbsp; 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
REPORT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT
TO SECTION&nbsp;13 OR 15(D)&nbsp;OF THE</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">SECURITIES
EXCHANGE ACT OF 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report
(Date of earliest event reported):&nbsp; <b>January&nbsp;20, 2009</b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">OMNICELL,
INC.</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of
registrant as specified in its charter)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center" style="color:black;font-size:12.0pt;margin:0in 0in .0001pt;text-autospace:none;">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-33043</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">94-3166458</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other
  jurisdiction of</font></p>
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">incorporation or
  organization)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File</font></p>
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification
  Number)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1201
Charleston Road</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Mountain
View, CA&nbsp; 94043</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of
principal executive offices, including zip code)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(650)
251-6100</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s
telephone number, including area code)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box
below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.7%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
  </td>
  <td width="96%" valign="top" style="padding:0in .7pt 0in .7pt;width:96.3%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Written communications
  pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.7%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="96%" valign="top" style="padding:0in .7pt 0in .7pt;width:96.3%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.7%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
  </td>
  <td width="96%" valign="top" style="padding:0in .7pt 0in .7pt;width:96.3%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Soliciting material
  pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.7%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="96%" valign="top" style="padding:0in .7pt 0in .7pt;width:96.3%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.7%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
  </td>
  <td width="96%" valign="top" style="padding:0in .7pt 0in .7pt;width:96.3%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pre-commencement
  communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17
  CFR 240.14d-2(b))</font></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.7%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="96%" valign="top" style="padding:0in .7pt 0in .7pt;width:96.3%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.7%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
  </td>
  <td width="96%" valign="top" style="padding:0in .7pt 0in .7pt;width:96.3%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pre-commencement
  communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17
  CFR 240.13e-4(c))</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;color:black;font-size:12.0pt;margin:0in 0in .0001pt;padding:1.0pt 0in 1.0pt 0in;text-autospace:none;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\jvangc\09-3556-1\task3307136\3556-1-ba.htm',USER='jvangb',CD='Jan 21 02:24 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;2.02
Results of Operations and Financial Condition</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On January&nbsp;20, 2009,
Omnicell,&nbsp;Inc. (&#147;Omnicell&#148;) issued a press release relating to its updated
2008 year end guidance and its initial guidance for its expected 2009 financial
results. The full text of the press release issued in connection with the
announcement is attached as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K
and is incorporated herein by reference.</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information in this Form&nbsp;8-K
and the Exhibit&nbsp;attached hereto shall not be deemed &#147;filed&#148; for purposes
of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange
Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
8.01 Other Events</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">On January&nbsp;20, 2009, Omnicell
also announced a company reorganization whereby </font><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">it appointed current executive, J.
Christopher Drew as Senior Vice President, Field Operations.&#160; In his new role, Mr.&nbsp;Drew will be
responsible for all of Omnicell&#146;s customer facing activities. Three general
managers each responsible for sales, field installation operations, and field
customer service in specific geographical areas of the United States and Canada
will report to Mr.&nbsp;Drew.&#160; Omnicell
also announced the addition of two vice presidents, Marga Ortigas-Wedekind as
Vice President, Marketing and Nhat Ngo as Vice President, Strategy and Business
Development. The full text of the press release issued in connection with the
announcement is attached as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K.</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;9.01
Financial Statements and Exhibits</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Exhibits</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="97%" style="border-collapse:collapse;width:97.0%;">
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.86%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:9.56%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.96%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="84%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:84.62%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description
  of Document</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.86%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="9%" valign="top" style="padding:0in .7pt 0in .7pt;width:9.56%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.96%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="84%" valign="top" style="padding:0in .7pt 0in .7pt;width:84.62%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release entitled
  &#147;Omnicell Updates 2008 Year End Guidance and Announces Company
  Reorganization&#148; dated January&nbsp;20, 2009.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\jvangc\09-3556-1\task3307136\3556-1-ba.htm',USER='jvangb',CD='Jan 21 02:24 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the
requirements of the Securities Exchange Act of 1934, as amended, the Registrant
has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="53%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:53.16%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OMNICELL,&nbsp; INC.</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:&nbsp;&nbsp;January&nbsp;20,
  2009</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:49.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Dan S. Johnston</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dan S. Johnston</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President and</font></p>
  </td>
 </tr>
 <tr>
  <td width="46%" valign="top" style="padding:0in .7pt 0in .7pt;width:46.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.74%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General Counsel</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\jvangc\09-3556-1\task3307136\3556-1-ba.htm',USER='jvangb',CD='Jan 21 02:24 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT
INDEX</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="7%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:7.78%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit</font></b><font size="1" style="font-size:8.0pt;">  <b>Number</b></font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="90%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:90.06%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="7%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:7.78%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="90%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:90.06%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release entitled
  &#147;Omnicell Updates 2008 Year End Guidance and Announces Company
  Reorganization&#148; dated January&nbsp;20, 2009.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\jvangc\09-3556-1\task3307136\3556-1-ba.htm',USER='jvangb',CD='Jan 21 02:24 2009' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a09-3556_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>

<html>

<head>





</head>

<body lang="EN-US" style="text-justify-trim:punctuation">

<div>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman"><img width="252" height="84" src="g35561mmi001.jpg"></font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For more information:</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deborah Reinert</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Omnicell,&nbsp;Inc.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investor Relations</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">800-850-6664, ext. 6403</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">deborah.reinert@omnicell.com</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="color:black;margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;font-weight:bold;">Omnicell Updates 2008 Year End Guidance and Announces Company
Reorganization</font></b></p>

<p align="center" style="color:black;margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;font-weight:bold;">MOUNTAIN VIEW, Calif., &#151; January&nbsp;20, 2009</font></b><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;"> &#151; Omnicell,&nbsp;Inc. (NASDAQ:
OMCL), a leading provider of system solutions to acute healthcare facilities,
today updated its 2008 year end guidance and provided initial guidance for
expected 2009 financial results. In addition, Omnicell announced a reorganization
focused on driving sales through higher levels of customer satisfaction.</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">Omnicell reconfirmed that it expects 2008 results to be
consistent with previous guidance of 18% revenue growth from 2007 and at the
higher end of previous guidance of $0.65 to 0.70 non-GAAP earnings per fully
diluted share, which excludes stock compensation expense.&#160; 2008 year end backlog is expected to be $110
million compared with 2007 year end backlog of $137 million, and lower than
previously expected.</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&#147;Economic conditions have caused some customers to postpone
orders,&#148; said Omnicell CEO, president and chairman Randall Lipps. &#147;We do not
expect customers to stop their acquisition process, but believe the sales cycle
will continue to be slow until the economic environment improves,&#148; Mr.&nbsp;Lipps
added. &#147;Order volume in the fourth quarter of 2008 was substantially less than
expected, especially in December.&#148;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">Omnicell now expects 2009 revenue of between $200 and $210
million and non-GAAP&#160; earnings per fully
diluted share of $0.30 to $0.35 excluding stock compensation expense.
Commenting on the forecast, Mr.&nbsp;Lipps added, &#147;Our systems sales forecast
reflects the challenging global economic and financial market environment.
Still, the patient safety initiatives that our systems support remain a
priority in hospitals, and to that affect we continue to secure contracts with
large healthcare institutions.&#160; However,
this will not preclude us from taking appropriate cost cutting measures in 2009
to balance our business with demand for our products while assuring we keep the
highest customer satisfaction standards in place.&#148;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">Today&#146;s announcement also includes a reorganization that will
place additional focus on driving sales through increased customer
satisfaction. Omnicell appointed longtime Omnicell executive, J. Christopher
Drew as senior vice president, field operations. Mr.&nbsp;Drew will be
responsible for all customer facing activities of the Company. Reporting to Mr.&nbsp;Drew
will be three seasoned general managers, each having 14+ years of sales and
service experience in the healthcare industry, and who will be responsible for
sales, field installation operations, and field customer service in specific
geographical areas of the United States and Canada. In this reorganization, the
position of vice president, sales, formerly held by Renee Luhr, will not be
filled. Ms.&nbsp;Luhr previously informed the company of her resignation
effective February&nbsp;15, 2009.</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">Omnicell also announced the addition of Marga
Ortigas-Wedekind as vice president, marketing and Nhat Ngo as vice president,
strategy and business development. Ms.&nbsp;Ortigas-Wedekind most recently
served as senior vice president, marketing, development, and clinical affairs
at Xoft,&nbsp;Inc. a manufacturer of radiation therapy products, and has more
than 18 years of marketing experience in the healthcare industry. Mr.&nbsp;Ngo
most recently served as vice president, business development and licensing at
Covidien, a global healthcare and supply company and held a number of senior
management positions at Britesmile, a cosmetic solutions company between 1999
and 2006.</font></p>

<p align="center" style="color:black;margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<div style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\c900193\09-3556-1\task3306746\3556-1-mm.htm',USER='C900193',CD='Jan 21 08:30 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="color:black;margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&#147;During the past year we have found that the alignment of our
functional organizations around customer focus drives increased satisfaction,
and ultimately, more sales opportunities,&#148; said Mr.&nbsp;Lipps. &#147;This
reorganization allows us to accelerate the speed of decision-making and
execution by pushing those functions closer to the customer. The addition of
Marga and Nhat to the executive team strengthens the development and execution
of our strategic initiatives.&#148;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;font-weight:bold;">Conference Call Scheduled</font></b></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Omnicell has scheduled a
conference call to answer questions regarding the Company&#146;s updated forecast
and reorganization changes at 8:30&nbsp;a.m. EST January&nbsp;21, 2009. The
conference call can be monitored by dialing 1-888-803-5209 within the U.S. or
1-706-679-1978 for all other locations. The conference ID # is 82021524.
Internet users can access the conference call via webcast at: www.omnicell.com.
A replay of the call will be available at approximately 9:00&nbsp;a.m. PST on January&nbsp;21,
2009 through 1:59&nbsp;p.m. PST on January&nbsp;28. The replay access numbers
are 1-800-642-1687 within the U.S. and 1-706-645-9291 for all other locations,
conference ID # 82021524.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">Omnicell is also scheduled to report its 2008 full fourth
quarter results in a webcast and conference call on January&nbsp;29, 2009, at
which point the Company will discuss in more detail the results of the fourth
quarter and year-end 2008 and guidance for 2009. Dial-in and webcast access
information will be available in the Investor Relations section of the Omnicell
website at: http://www.omnicell.com.</font></p>

<p style="color:black;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Omnicell</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Omnicell,&nbsp;Inc.
(NASDAQ: OMCL) is a leading provider of systems and software solutions
targeting patient safety and operational efficiency in healthcare facilities.
Since 1992, Omnicell has worked to enhance patient safety and allow clinicians
to spend more time with their patients.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Omnicell&#146;s medication-use
product line includes solutions for the central pharmacy, nursing unit,
operating room, and patient bedside. Solutions range from large central
pharmacy smart inventory carousels to small handheld devices. From the point at
which a medication arrives at the receiving dock to the time it is
administered, Omnicell systems store it, package it, bar code it, order it,
issue it, and provide information and controls on its use and reorder.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our supply product lines
provide a healthcare institution with fast, effective control of costs, capture
of charges for payer reimbursement, and timely reorder of supplies. Products
range from high-security closed-cabinet systems and software to open-shelf and
combination solutions in the nursing unit, catheter lab and operating room.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Omnicell&#146;s mission is to
provide the best customer experience in healthcare, helping hospitals reduce
medication errors, operate more efficiently, and decrease costs. For more
information, visit www.omnicell.com.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;font-weight:normal;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;font-weight:bold;">Forward-Looking
Statements</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="color:black;font-weight:normal;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" color="black" face="Times New Roman" style="color:windowtext;font-size:10.0pt;">To the extent any statements
contained in this release deal with information that is not historical, these statements
are necessarily forward-looking. As such, they are subject to the occurrence of
many events outside Omnicell&#146;s control and are subject to various risk factors
that could cause actual results to differ materially from those expressed or
implied in any forward-looking statement. The risk factors are described in the
Company&#146;s Securities and Exchange Commission (SEC) filings and include, without
limitation, the unfavorable general economic and market conditions, the
tightening in the credit markets, the continued growth and acceptance of our
products and services and the continued growth of the clinical automation and
workflow automation market generally, the potential of increasing competition,
the ability of the company to grow product backlog, retain key personnel,&#160; develop new products and integrate acquired
products or intellectual property in a timely and cost-effective manner, and
improve sales productivity. Prospective investors are cautioned not to place
undue reliance on forward-looking statements.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OMCL-E</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">###</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\c900193\09-3556-1\task3306746\3556-1-mm.htm',USER='C900193',CD='Jan 21 08:30 2009' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g35561mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g35561mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!4`/P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BJESJEC:<3W4:G^[G)_(5ES^+K).(8I
M93ZXVC]:RG6IP^*1#G%;LWZ*Y";QA=MD0VT4?NQ+&J4OB/59.MSL'^PH%<TL
M=26UV9NO!'>4UF5?O,!]37GXN=4O#A9KJ;/92Q_E4J:%J]QR;:0>\C8_F:A8
MUR^"#8O;-[([9KVT3[]S"OU<5"VL::G6]A_[[%<S'X1U!OOO!'^)/]*LIX-D
M_P"6EZH_W8\_UJO;8A[0'SU'M$V3K^E#K>Q_ADTP^(])'_+V#]$;_"J"^#8!
M]Z\E/T4"I5\(6`^]+.W_``(#^E5S8I_97]?,=ZO9%G_A)=)_Y^3_`-\-_A2?
M\)-I7_/P?^^&_P`*B'A/3!U\X_\`;2G#PMI8_P"6<A_[:&G?%=E^(?O?(D'B
M72?^?K_QQO\`"G#Q%I)_Y?%'U5O\*C_X1?2O^>+_`/?PT?\`"+Z5_P`\7_[^
M&G?%?W?Q'^]\B<:]I3=+V/\`'(J1=7TYNE[#_P!]BJ9\+:6?^6<@_P"VAIA\
M)Z6>TP_[:4[XGLOQ"]3LC46]M7^[<PGZ.*E5T;[K`_0UAMX0TX]'G'_`A_A3
M/^$0MA_J[N=/RI\]=;P7WCYI]CH:*Y\>&9X_]3J]PGY_XT\:5K<7^KUG=_UT
M3-/VM3K!_>@YI=8F[16*$\1Q?\M;.<>X*U(+W68_]=I22#UBF']:KVRZIKY?
MY#Y^Z-:BLQ=8*_\`'QIUY%[^7N'YBIH]7L)#C[2J'TDRA_6J56#ZCYEW+M%-
M5U==R,&'J#FG5H4%%%%`!11574VF33;AH,^8(SMQUI2=DV)NRN9^J>)+>P9H
M81Y\XZ@'Y5^IKF;S6]0OB1).50_P1_**H=>:*\"KB:E1[V1P3JRD%6+2QN;Z
M3R[:%I#W/8?4TEE;_:[V&WW;?,<*3Z5Z%;6L-G`L,"!$7L.]7AL-[9W;T15.
MGSG/6?@\8#7EP3_L1?XFM>#1M,LEWK;1C:,EY.<>^36A7#_$W6GLM,ATR!RK
MW9)D(Z[!V_$_RKUH8>E3V1UQIQCLB'6?B9;VLQM=%M%NBIV^:^0A/^R!R?TK
M*'Q*\0VLRF\T^#8W.QHWC)'L2:Z/P!X:M].TB+4IXE:\NEWAF',:'H!Z<<UK
M^+;*WOO#-\MPBGRX6D1B.58#((K8L?X=\0VGB/3_`+5;`HR';+$W5#_4>]:U
M>6_"^<P7>J2,2(DM@[^F03_3-)H_C7Q7J=Y-!:1K>2,A\M/+55CY^\3QT%%P
M/4Z*\C/C'Q5H>M^7JLK.8V'FV[JN"I]".G'0U:USQ!XWAC75)8WT^RD;$:*J
MG&>F[//YT7`]2HKE-#\4SWW@JZU:Z"K<6JR*S*,!F`R#C\17+Z-XR\7:IY]M
M:1K>7+*-K")56$=R>@],9HN!ZG63XFU=]"T*>_BC625-H1&S@DD#M7G0\7^*
MM!UH0:K*TA5AYD$BK@J?0BNL\?\`B2]T*TLQI\JQS3NQ)9`WR@>A]R*+@7_!
MVNWWB'3);R]MXH<2E$$8(R`!D\_6N@KE3XI?1O!=GJ>J$3WER@*1J`N]CR.G
M0`8S7*KK7CS6K>34;(/':KDCRD51@=<9Y:BX'JE%</X#\8W>M3RZ?J11YDC\
MQ)E&W<`<$$=.XJGJ_CC5M4U=M*\+P[MI*^<%#,^.I&>`ON:+@>B5F^(-5_L7
M0[K4`BNT*Y5&.`Q)P!^M>=3>)_&/AC4(UU=C(K_-Y<@4AU[X9>AK<^(VJQS>
M%++R3\M](L@_W0N[^HHN!I^&?%=SK6C7^I7=K%!':YV[&)W87)Z_A4/@WQA>
M^)KRXCFLH8(H(PVY&)))/`Y_&L>/_B4?")F^[)>_^SMC_P!!%7OA99^5HEU=
MD<SS[1]%'^)-`&R-?N3J&SR$\C?M[[L;MO7IG/:MUD1QAU##T(S4']GVGVG[
M3]G3S<[MV._K]?>K-`%8Z?:;MP@5#ZI\O\JD2'RSQ(Y'HQS4M%)12V0K(***
M*H84444`8>I>%[:[=I;=OL\AY(`RI/T[5S]UX>U.U)_<>:O]Z(Y_3K7>45R5
M,'2GKLS&5&,CS13+:SJ^&CD1@1N&""*[;2=>MM1149A%<8Y0GK]/6M*2&*9=
MLL:./1E!K/F\/:7-R;4(?6,E?Y5G2P]2B[P=UYBC3E!Z,TZ\F^*)<^)8@V=H
MM5V_]]-FO3+:PDM&`CO9GB'_`"SEPWY'K61XP\))XEMHWBD$-Y!GRW8?*P/5
M37:FVM58V3[FQI,L,^D6<L#!HFA3:1Z8%<U\1==AL-$?34D!NKP;=H/*IW)_
ME^-<Q;>&_'FE`VMBTT41/_+*Y79]>3Q6IHWPWN9KP7OB*Y\TD[FA5RQ<_P"T
MWI]*8REH]J^B_#C5-3D&R74%"19Z[#\H_/)-:GPJLMFFWMZ5YEE$:GV49_F:
MU_&NB:AK.C0:?IB1!5E#.&;:`H!P!5SPMI$VA^&X+*4(;A=S.%.06))Z_E18
M#S^Z`UWXI^61OC6Z"D?[,8Y_]!-=%\4[ORM#MK0'F>?<?HH_Q(J/PCX/U72_
M$<FJ:F(<%'*['W'<Q^GIFI?'7A?6/$5_;-9"'R(8B/GDP=Q//&/0"ET`RKK_
M`(E/PD@B^[)?R`GWW,6_DHK<^&=D+?PR;DKA[J9FSZJ.!_(_G4?B_P`+ZGJN
MG:98::L/E6B8;>^WD``?UKI-#T]M*T*SL6P7@B"M@\%N_P"N:8'FNM_\3OXG
MK;#E%N(XOP7!;^M2?$>9K_Q9;:?'SY<:1@?[3G_]5;/AKP?JUEXL?5]3$.PF
M1QLDW'<WX>A-!\'ZM<^//[9NEA^R"Y\P8DRVU1\O&/84@,'XAR%M?M-+4XBM
M+=(T'8$]_P`L?E7I^;/1=)7S72"UM8@I8]%`XKE/''@JZUN[34=-9#.$"21.
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MTC2$.`HRP'HB@#^==9X.L_L/A33XB,,T0D;ZM\W]:Y_QIX3UCQ#KD,]L(?LL
M4:IEY,'J2QQCWKN(HUAB2)!A44*/H*?4!]%%%,`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
@B@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
